NEW YORK — Patients with established intravitreal injection treatment for age-related macular degeneration were 2.35 times less likely to be lost to follow-up during the pandemic compared with the total ophthalmology patient population.
In a poster presented at the American Society of Retina Specialists annual meeting, Leonard Ginsburg, MD, and colleagues presented the results of a retrospective analysis conducted at seven nonacademic practices (six multispecialty and one retina only) in six U.S. states. In the year preceding the pandemic, 92,359 patients were seen, 6,801 were diagnosed